Publications

Bleve S, Ravera F, Rodrigues S, Pederzoli F, Pakula H, Brighi N, Giunta EFrancesco, Schepisi G, Virga A, Gurioli G et al..  2026.  Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.. Prostate Cancer Prostatic Dis.

Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, Ouerfelli O, Socciarelli F, Frankenstein Z, Dong H et al..  2026.  NSD2 targeting reverses plasticity and drug resistance in prostate cancer.. Nature. 649(8095):216-226.

Omar M, Fanelli GNicolo', Socciarelli F, Ullanat V, Puchala SReddy, Wen J, Chowdhury A, Valencia I, Scatena C, Marchionni L et al..  2025.  Antibody-Based Multiplex Image Analysis: Standard Analytical Workflows and Artificial Intelligence Tools for Pathologists.. Lab Invest. 105(10):104220.

Fanelli GNicolò, Nuzzo PVitale, Pederzoli F, Loda M.  2025.  Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.. Surg Pathol Clin. 18(1):25-39.

Tamarindo GH, Ribeiro CF, Rodrigues S, Góes RM, Loda M.  2025.  DHA suppresses hormone-sensitive and castration-resistant prostate cancer growth by decreasing de novo lipogenesis.. Biochim Biophys Acta Mol Cell Biol Lipids. 1870(5):159634.

Morelli E, Ribeiro CFidalgo, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C et al..  2025.  Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.. Clin Cancer Res. 31(10):1975-1987.

Nuzzo PVitale, Rodrigues S, Ribeiro CFidalgo, Teixeira IFerrari, Fanelli GNicolo', Bleve S, Ravera F, Pakula H, Pederzoli F, Nanus DM et al..  2025.  Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors.. Crit Rev Oncol Hematol. 214:104910.

Ribeiro CFidalgo, Rodrigues S, Bastos DCampanella, Fanelli GNicolò, Pakula H, Foiani M, Zadra G, Loda M.  2024.  Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.. Sci Signal. 17(831):eadh1922.

Pakula H, Pederzoli F, Fanelli GNicolò, Nuzzo PVitale, Rodrigues S, Loda M.  2024.  Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.. Cancers (Basel). 16(21)

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GNicolò, Pannellini T, Socciarelli F, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C et al..  2024.  Distinct mesenchymal cell states mediate prostate cancer progression.. Nat Commun. 15(1):363.

Haffner MC, Morris MJ, Ding C-KC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R et al..  2024.  Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.. Clin Cancer Res.

Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, Homsy K, Imada EL, Syamala S, Photopoulos C et al..  2024.  Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.. Cancer Res. 84(11):1834-1855.

Tamarindo GHenrique, Ribeiro CFidalgo, Silva ADella Torr, Castro A, Caruso ÍPutinhon, Souza FPereira, Taboga SRoberto, Loda M, Góes RMaira.  2024.  The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.. Cancer Metab. 12(1):24.

Omar M, Xu Z, Rand SB, Alexanderani MK, Salles DC, Valencia I, Schaeffer EM, Robinson BD, Lotan TL, Loda M et al..  2024.  Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images.. Mol Cancer Res. 22(4):347-359.

Ma C, Zhou Y, Fanelli GNicolò, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL.  2023.  The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.. Mol Cancer Res. 21(3):253-260.

Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PVitale, Loda M.  2023.  "Stromal cells in prostate cancer pathobiology: friends or foes?". Br J Cancer. 128(6):930-939.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M et al..  2022.  Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.. Mol Cancer Res. 20(5):673-685.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, Hari SN, Van Allen EM, Marchionni L, Umeton R et al..  2022.  Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology.. Mol Cancer Res. 20(2):202-206.

Francini E, Fanelli GNicolò, Pederzoli F, Spisak S, Minonne E, Raffo M, Pakula H, Tisza V, Scatena C, Naccarato AGiuseppe et al..  2022.  Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.. Cancers (Basel). 14(18)

Choi SYC, Ribeiro CFidalgo, Wang Y, Loda M, Plymate SR, Uo T.  2022.  Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.. Biomolecules. 12(11)

Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y et al..  2022.  MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.. Nat Commun. 13(1):2559.

Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM.  2022.  O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.. J Biomed Sci. 29(1):13.

Davidson SM, Schmidt DR, Heyman JE, O'Brien JP, Liu AC, Israelsen WJ, Dayton TL, Sehgal R, Bronson RT, Freinkman E et al..  2022.  Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.. Cancer Res. 82(13):2403-2416.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM et al..  2021.  ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.. Cancer Res. 81(7):1704-1718.

Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, Mucci L, Roberts T, Zanata SM, Zadra G et al..  2021.  Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.. J Pathol. 253(3):292-303.